medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2004, Number 2

<< Back Next >>

Rev Biomed 2004; 15 (2)

Treatment of the spasticity in the infantile cerebral palsy with botulinum toxin

Ojeda-Manzano A

Language: Spanish
References: 16
Page: 107-112
PDF size: 53.03 Kb.


ABSTRACT

Introduction. One of the factors that contributes to the disability of a child with infantile cerebral palsy (ICP) it is the presence of spasticity as a restrictive factor of the function of motor muscles. Botulinum Toxin type A (BTA) injected inside the spastic musculature, is a new therapeutic modality in this type of patient.
Clinical case. A 6 year-old female patient with a background of ICP caused by neonatal asphyxia and with a clinical record of spastic tetraparesis was examined. BTA was injected into the muscles selected by clinical exploration. A response was considered positive to the treatment: on the decrease in the degree according to Ashworth's scale and the same score or superior at three in the scale of global improvement of O´Brien. The treatment with BTA was accompanied at all times by physical therapy. After two months of injection with BTA the following results were obtained: According to the scale of Ashworth a grade 4 diminished to a grade 3 in the biceps cruris, semitendinosus, semimembranosus, and flexor pollicis brevis muscles; and a grade 4 to a grade 2 in the same scale in the flexor digitorum sublimiss, biceps braquialis and braquiradialis muscles; and according to O´Brien's scale it was considered a grade 5.
Discussion. The good results of the use of BTA accompanied by appropriate physical therapy in the spasticity problems in the patient with ICP have once again been proved in this case. The intensity of the effect of BTA depends on the spasticity in each different case, previous treatment, patient’s sensitivity to BTA, technical application and physical therapy after the application.


REFERENCES

  1. Roslyn B, Grahan HK. Botulinum toxin A in the management of children with cerebral palsy: indications and outcomes. Eur J Neurol 1997; 4 (Suppl 2):15-22.

  2. Davis EC, Barnes MP. Botulinum toxin and spasticity. J Neurol Neurosurg Psych 2000; 69: 143-7.

  3. Singer C. Indicaciones y manejo de la toxina botulínica. Rev Ecua Neurol 2000; 9 (1 y 2). En http://www.medicosecuador.com/revecuatneurol/Vol9_n1-2_2000.html

  4. Herrera-Galante A, Pérez-Fernández F, Flores-Jurado M, Gómez-González A, Godoy-Ramírez AM. Tratamiento de la espasticidad con toxina botulínica en la parálisis cerebral infantil. Rehabilitación 1999; 33: 304 - 9

  5. Arnold SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Asher MS, et al. Botulinum toxin as a biological weapon. JAMA 2001; 285: 1059-70.

  6. Aguilar-Rebolledo F, Hernández-Sanchez J, Rayo-Mares D, Soriano-Fonseca F, García-Muñoz L, Ruiz-Ponce J, et al. Toxina Botulínica como tratamiento de la espasticidad y distonía de la parálisis cerebral infantil. Gac Méd Méx 2001; 137:403-11.

  7. Cosgrove AP, Corry IS, Graham HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994; 36: 386-96.

  8. Churotian AM, Root L. Management of spasticity inchildren with Botulinum-A toxin. Int Pediatr 1994; 9: 129-37.

  9. Gormley ME, Herring GM, Gaebler-Spira D. The use of botulinum toxin in children: a retrospective study of adverse reactions and treatment of idiophatic toe-walking. Eur J Neurol 1997; 4 (Suppl 2): 27-30.

  10. Aguilar-Rebolledo F. Pascual-Pascual S.I. Tratamientos farmacológicos para la parálisis cerebral. I Tratamiento de la Espasticidad. Plasticidad y Restauración neurológica. Plast & rest neurol 2002; 1: 23-32.

  11. Dune JW, Heye N, Dunne SL. Treatment for chronic limb spasticity with botulinum toxin A. J Neurol Neurosurg Psychiatriy 1995; 58:232-5.

  12. Chutorian A, Root L, BTA Study Group. A multicenter randomized, double-mind, placebo controlled trial of Botulinum toxin type A (BTA) in the treatment of lower limb spasticity in pediatric cerebral palsy. Mov Disord 1995; 10:364.

  13. Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM, et al. Botulinum toxin type A in the treatment of upper extremity. A randomized, double-blind, placebo-controlled trial. Neurology 1996; 46:1306-10.

  14. Pullman SL, Greene P, Fahn S, Pedersen SF. Approach to the treatment of limb disorders with Botulinum toxin A. Experience with 187 patients. Arch Neurol 1996; 53:617-24.

  15. Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995; 45: 712-7.

  16. Ruiz-Martínez BA, Salas-Roldán E. Toxina botulínica y fisioterapia en la parálisis cerebral infantil. Fisioterapia 2002; 24:128-31.




2020     |     www.medigraphic.com